Ignite Creation Date:
2024-05-06 @ 9:57 AM
Last Modification Date:
2024-10-26 @ 12:22 PM
Study NCT ID:
NCT03118661
Status:
WITHDRAWN
Last Update Posted:
2018-11-07
First Post:
2017-04-13
Brief Title:
Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Effect of CCR5 Inhibition by Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant for Any Indication and Its Observed Effect on Graft Versus Host Disease and HIV-1 Persistence
Status:
WITHDRAWN
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No accrual to the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this proposal is to determine the effect of maraviroc when it has been a part of the antiretroviral ART regimen given immediately after allogeneic hematopoietic cell transplant allo-HCT for HIV-1 infected participants who have a hematopoietic malignancy or other underlying disorder requiring an allogeneic transplant Maraviroc has been given in practice to alleviate symptoms of graft vs host disease GvHD Given its mechanism of action it may also have an effect on the reservoir size of HIV-1 in infected patients This study will inform potential future studies evaluating the effect of this approach on the incidence and severity of GvHD and determining its effect on HIV-1 reservoir
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None